vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and LiveRamp Holdings, Inc. (RAMP). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $212.2M, roughly 1.3× LiveRamp Holdings, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 18.8%, a 77.5% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 8.6%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 11.1%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
ACAD vs RAMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $212.2M |
| Net Profit | $273.6M | $39.9M |
| Gross Margin | 90.8% | 71.9% |
| Operating Margin | 6.1% | 18.6% |
| Net Margin | 96.3% | 18.8% |
| Revenue YoY | 9.4% | 8.6% |
| Net Profit YoY | 90.3% | 255.7% |
| EPS (diluted) | $1.61 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $212.2M | ||
| Q3 25 | $278.6M | $199.8M | ||
| Q2 25 | $264.6M | $194.8M | ||
| Q1 25 | $244.3M | $188.7M | ||
| Q4 24 | $259.6M | $195.4M | ||
| Q3 24 | $250.4M | $185.5M | ||
| Q2 24 | $242.0M | $176.0M | ||
| Q1 24 | $205.8M | $171.9M |
| Q4 25 | $273.6M | $39.9M | ||
| Q3 25 | $71.8M | $27.4M | ||
| Q2 25 | $26.7M | $7.7M | ||
| Q1 25 | $19.0M | $-6.3M | ||
| Q4 24 | $143.7M | $11.2M | ||
| Q3 24 | $32.8M | $1.7M | ||
| Q2 24 | $33.4M | $-7.5M | ||
| Q1 24 | $16.6M | $-5.4M |
| Q4 25 | 90.8% | 71.9% | ||
| Q3 25 | 92.2% | 70.2% | ||
| Q2 25 | 92.2% | 70.1% | ||
| Q1 25 | 91.7% | 69.3% | ||
| Q4 24 | 91.6% | 71.9% | ||
| Q3 24 | 92.5% | 72.4% | ||
| Q2 24 | 92.5% | 70.6% | ||
| Q1 24 | 88.8% | 72.2% |
| Q4 25 | 6.1% | 18.6% | ||
| Q3 25 | 12.8% | 10.7% | ||
| Q2 25 | 12.2% | 3.7% | ||
| Q1 25 | 7.9% | -6.1% | ||
| Q4 24 | 59.1% | 7.5% | ||
| Q3 24 | 12.6% | 4.0% | ||
| Q2 24 | 12.6% | -3.0% | ||
| Q1 24 | 7.4% | -8.3% |
| Q4 25 | 96.3% | 18.8% | ||
| Q3 25 | 25.8% | 13.7% | ||
| Q2 25 | 10.1% | 4.0% | ||
| Q1 25 | 7.8% | -3.3% | ||
| Q4 24 | 55.4% | 5.7% | ||
| Q3 24 | 13.1% | 0.9% | ||
| Q2 24 | 13.8% | -4.3% | ||
| Q1 24 | 8.0% | -3.1% |
| Q4 25 | $1.61 | $0.62 | ||
| Q3 25 | $0.42 | $0.42 | ||
| Q2 25 | $0.16 | $0.12 | ||
| Q1 25 | $0.11 | $-0.10 | ||
| Q4 24 | $0.86 | $0.17 | ||
| Q3 24 | $0.20 | $0.03 | ||
| Q2 24 | $0.20 | $-0.11 | ||
| Q1 24 | $0.10 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $403.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $962.3M |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $403.4M | ||
| Q3 25 | $258.0M | $376.9M | ||
| Q2 25 | $253.6M | $371.1M | ||
| Q1 25 | $217.7M | $420.8M | ||
| Q4 24 | $319.6M | $384.3M | ||
| Q3 24 | $155.1M | $348.4M | ||
| Q2 24 | $177.1M | $342.7M | ||
| Q1 24 | $204.7M | $368.9M |
| Q4 25 | $1.2B | $962.3M | ||
| Q3 25 | $917.3M | $943.8M | ||
| Q2 25 | $822.4M | $947.8M | ||
| Q1 25 | $765.2M | $948.9M | ||
| Q4 24 | $732.8M | $957.7M | ||
| Q3 24 | $577.2M | $932.1M | ||
| Q2 24 | $516.7M | $951.9M | ||
| Q1 24 | $464.0M | $949.1M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.3B | ||
| Q3 24 | $976.9M | $1.2B | ||
| Q2 24 | $914.1M | $1.2B | ||
| Q1 24 | $855.1M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | — | ||
| Q3 25 | $74.3M | $57.4M | ||
| Q2 25 | $64.0M | $-15.8M | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | $40.4M | $45.1M | ||
| Q3 24 | $63.2M | $55.6M | ||
| Q2 24 | $25.0M | $-9.3M | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | $56.8M | ||
| Q2 25 | — | $-16.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $44.8M | ||
| Q3 24 | $63.2M | $55.4M | ||
| Q2 24 | — | $-9.6M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | 28.4% | ||
| Q2 25 | — | -8.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 22.9% | ||
| Q3 24 | 25.2% | 29.8% | ||
| Q2 24 | — | -5.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.1% | 0.3% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 2.09× | ||
| Q2 25 | 2.40× | -2.04× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | 4.02× | ||
| Q3 24 | 1.93× | 32.10× | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
RAMP
Segment breakdown not available.
